to critically review the potential effect of the public reporting of pharmaceutical company payments to healthcare professionals on the relationship between medicine and industry.

this review is based on an examination of the ‘Transparency Model’ put out recently for consultation by Medicines Australia.

public reporting in itself will neither sharpen the boundaries between medicine and the pharmaceutical industry nor restore public confidence.

focusing on payments for clinical research and on the larger payments to healthcare professionals would lead to a better understanding of the interplay between science and marketing.